Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 May 2022
Robert Frater
The research efforts in the Department of Cardiothoracic Surgery in the Faculty of Health Sciences, UFS, have come a long way since the establishment of a homograft bank, animal research, and laboratory-based research on cardioplegia by Prof Hannes Meyer in the 1980s

Several world-class scientists and academics in the field of cardiovascular research will converge at the University of the Free State (UFS) on Thursday (5 May 2022) for a one-day hybrid conference to explore and celebrate the massive strides made in this critical field at the UFS Robert W M Frater Cardiovascular Research Centre.

The research efforts in the Department of Cardiothoracic Surgery in the Faculty of Health Sciences, UFS, have come a long way since the establishment of a homograft bank, animal research, and laboratory-based research on cardioplegia by Prof Hannes Meyer in the 1980s. Renewed interest in 2004 under the leadership of Prof Francis E Smit culminated in the establishment of the Robert W M Frater Cardiovascular Research Centre (the Frater Centre) in 2015. This was made possible through donor funding, especially by Dr Robert W M Frater MD PhD (honoris causa, UFS), a South Africa-born New York-based cardiothoracic surgeon, researcher and innovator as infrastructure and project support by the UFS.

The vision of the Frater Centre is to be a leading cardiovascular research institution in South Africa and sub-Saharan Africa. It provides an interdisciplinary training and research platform for scientists and clinicians from different backgrounds to develop as researchers and collaborators in cardiovascular and thoracic surgery and related domains. Activities are focused on the development of African solutions for African problems.

Three main divisions
The Frater Celebration day will highlight the achievements made thus far in a hybrid format in four sessions, which can be attended on a virtual platform or in person. The centre’s local and international collaborators will participate in the programme, and Dr Ronnie van der Merwe, the Group CEO of Mediclinic International, is the guest of honour.

The Frater Centre consists of three main divisions, all of which will form part of the focus of the conference programme in various forms during the day:

1) The Clinical Research Division addresses cardiovascular disease on a broad front, ranging from population and prevalence studies, healthcare solutions and clinical outcomes studies in a specific South African and African context.

2) The Research, Development and Commercialisation division is divided into Tissue Engineering and Cell Biology, Tissue Banking and Large Animal studies, and bioengineering to develop African solutions and technology within these domains.

3) The Simulation Programme provides an integrated interdisciplinary platform for the education and training of individuals and teams in cardiovascular, thoracic, anaesthetic, perfusion technology and related nursing fields in a state-of-the-art simulation unit. The research centre is developing a unique and leading programme and systems in this field. This endeavour is also developing IT models for training, evaluation and research.

The Frater Centre and 4IR
The Centre is firmly established in the fourth industrial revolution. It is new technology-driven, creating new IT platforms and boasts extensive interdisciplinary projects at the biomedical sector's local, national, and international levels.

It is essential to note that the extensive and successful collaboration within the Frater Centre not only exists on institutional level but also nationally and internationally. These collaborators assist, mentor, direct and contribute to the research activities.

Click: Link to the event
Event programme



News Archive

Nano research at the UFS opens door to smart drugs
2011-06-27

 

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences. 

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.
 
Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).
 
Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.
  
These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept